Blackstone Inc. closed its latest life-sciences fund with $6.3 billion of commitments, the firm’s biggest haul for backing ...
By Kamal Choudhury March 26 (Reuters) - Wave Life Sciences shares plunged 58% on Thursday after a higher dose of its experimental obesity drug failed to show a clear improvement at reducing a ...
The post-pandemic bubble popped, but life sciences aren’t going anywhere. Blackstone announced Monday that it closed ...
Wave Life Sciences (WVE) stock plunges as the company interim data from an early-stage trial for WVE-007, its RNA-based ...
Blackstone (NYSE: BX) today announced the final close of Blackstone Life Sciences VI ("BXLS VI"). BXLS VI was oversubscribed ...
Wave Life Sciences (NASDAQ:WVE) shares are trading near historic lows after two Wall Street firms cut their price targets ...
Dialogue continues with European Medicines Agency (EMA) to advance the development program of oral blarcamesine in early Alzheimer’s ...
Joseph Kadlec and Douglas Gray of Troutman Pepper Locke LLP discuss how life sciences companies can position themselves for M&A acquisition amid Big Pharma's search for new pipeline assets.
We recently compiled a list of the 13 Best Stocks to Invest In on Robinhood for Beginners. Wave Life Sciences Ltd. is among the best Robinhood stocks to invest in. TheFly reported earlier on March 10 ...
Read about the new Biocom Octane partnership. Discover how this collaboration expands capital and accelerator access for ...
Dr. Mark Turco "will step down" from his role with the Hub Wednesday, March 11, to lead a medical device company.
Barchart on MSN
Wave Life Sciences crashes deep into oversold territory as obesity drug data disappoints. Should you buy the dip?
Wave Life Sciences (WVE) shares crashed more than 50% on Mardh 26 after the company’s interim Phase 1 data for its obesity ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results